Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Thesla Palanee‐Phillips et al.|New England Journal of Medicine|2016Cited by 768
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in WomenJared M. Baeten, Zeda Rosenberg, Thesla Palanee‐Phillips et al.|Obstetrical & Gynecological Survey|2016Cited by 373
Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension studyJared M. Baeten, Samuel Albert, Thesla Palanee‐Phillips et al.|The Lancet HIV|2021Cited by 111
PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration projectConnie Celum, Elizabeth A. Bukusi, Linda‐Gail Bekker et al.|Journal of the International AIDS Society|2022Cited by 95
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trialGonasagrie Nair, Kenneth Ngure, Connie Celum et al.|The Lancet HIV|2023Cited by 62